A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies the safety and effect of Gimatecan in patients with
platinum-resistant recurrent epithelial ovarian, fallopian tube or peritoneal cancer.
The chemotherapy will be given every four weeks.This study is a single-arm, multi-center
research design.